Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy.

MLA

Gianni, Luca, et al. “Feasibility and Tolerability of Sequential Doxorubicin/Paclitaxel Followed by Cyclophosphamide, Methotrexate, and Fluorouracil and Its Effects on Tumor Response as Preoperative Therapy.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 11, no. 24 Pt 1, Dec. 2005, pp. 8715–21. EBSCOhost, https://doi.org/10.1158/1078-0432.CCR-05-0539.

APA

Gianni, L., Baselga, J., Eiermann, W., Guillem Porta, V., Semiglazov, V., Lluch, A., Zambetti, M., Sabadell, D., Raab, G., Llombart Cussac, A., Bozhok, A., Martinez-Agulló, A., Greco, M., Byakhov, M., Lopez Lopez, J. J., Mansutti, M., Valagussa, P., & Bonadonna, G. (2005). Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 11(24 Pt 1), 8715–8721. https://doi.org/10.1158/1078-0432.CCR-05-0539

Chicago

Gianni, Luca, José Baselga, Wolfgang Eiermann, Vicente Guillem Porta, Vladimir Semiglazov, Aña Lluch, Milvia Zambetti, et al. 2005. “Feasibility and Tolerability of Sequential Doxorubicin/Paclitaxel Followed by Cyclophosphamide, Methotrexate, and Fluorouracil and Its Effects on Tumor Response as Preoperative Therapy.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 11 (24 Pt 1): 8715–21. doi:10.1158/1078-0432.CCR-05-0539.